Micro Labs has been in a continuous stage of growth ever since it’s founding years and continues to chart its course as a leader in the pharmaceutical vertical. The company has presence in over 30 countries with ground level operations in 15 countries, exporting all major dosages on most of the therapeutic segments. We are poised to have a quantum leap in our global operations, with implementation of our growth strategies. The company currently operates in various countries of Asia, Europe, America & Africa. Micro Labs has already established a strong presence in USA, UK, Russia, Ukraine, Nigeria, French West Africa, East Africa, Myanmar, Philippines, Vietnam, Thailand, Sri Lanka, etc. Latin America, North America, East Europe, Australia, New Zealand and North Africa are locations where the company is raising its flag. The company also has plans to spread its wings in countries like Canada, South Africa, UAE, etc.
To complement our vision for global operations, company has established wholly owned subsidiaries in the USA (Micro Labs USA Inc.) , UK (Brown & Burk UK Ltd), Germany (Micro Labs GmbH), Australia (Micro Labs Pty Ltd) and Nigeria (Micro Nova Pharmaceuticals Ind Ltd). The Company has Representative Offices in many other parts of the world (emerging markets).
At Micro Labs, we are dedicated to developing top of the line pharmaceutical products, while adhering to highest quality standards by a world class research team. The continuous strive for perfection has led us to push our standards of manufacturing by building state-of-the-art facilities. Today these state-of-the-art manufacturing facilities and infrastructure facilitate Micro’s Organic Growth in the regulated markets.
The reason why Micro Labs has been able to have a successful run abroad is its world-class manufacturing units. Some of our facilities have been approved by the following regulatory authorities:
Food & Drugs Control Administration (FDA) , US
Medicines & Healthcare products Regulatory Agency (MHRA), UK
World Health Organisation (WHO)
Therapeutic Goods Authority (TGA), Australia
Medsafe, New Zealand
Ministry of Health (MoH) of may countries of the emerging market.
The patient’s identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not disclose the reporter’s identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the reaction.